Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Lyra Therapeutics, Inc. is not a good value stock. Lyra Therapeutics, Inc. is a mediocre stock to choose.

News

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $7.13 Average Target Price from Analysts

Zolmax Shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) have been given a consensus rating of "Hold" by the six analysts that are covering the firm, MarketBeat reports. One research...\n more…

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $7.13 Consensus Target Price from Brokerages

Ticker Report Shares of Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) have earned a consensus recommendation of "Hold" from the six brokerages that are covering the stock, MarketBeat reports. One analyst...\n more…

Lyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Up 18.6% in August

Zolmax Lyra Therapeutics, Inc. (NASDAQ:LYRA - Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 4,150,000 shares, a growth...\n more…

Despite Recent Gains, Lyra Therapeutics Insiders Are Still Down US$66k

Simply Wall St Insiders who purchased US$74.1k worth of Lyra Therapeutics, Inc. ( NASDAQ:LYRA ) shares over the past year recouped...\n more…

Equities Analysts Set Expectations for Lyra Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:LYRA)

Ticker Report Lyra Therapeutics, Inc. (NASDAQ:LYRA - Free Report) - Analysts at William Blair increased their Q3 2024 earnings per share (EPS) estimates for shares of Lyra Therapeutics in a research note issued to...\n more…

Lyra Therapeutics (NASDAQ:LYRA) Earns "Neutral" Rating from HC Wainwright

Ticker Report HC Wainwright reiterated their neutral rating on shares of Lyra Therapeutics (NASDAQ:LYRA - Free Report) in a report issued on Thursday morning, Benzinga reports. They currently have a $2.00 price...\n more…